Sucampo bags rare disease player Vtesse in $200M buyout agreement
Just a little more than two years after it was launched, the single-asset biotech Vtesse is being bought out by Sucampo for $200 million up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
